Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

DENTSPLY SIRONA Inc. XRAY

Dividend Yield: 4.11%
Mizuho analyst Steven Valiquette maintained a Neutral rating and cut the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 60%.
Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 76%.
Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.
Benzinga Pro’s real-time newsfeed alerted to latest XRAY news.

Bristol-Myers Squibb Company BMY

Dividend Yield: 4.06%
Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 73%.
Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating and increased the price target from $50 to $55 on Feb. 4, 2025. This analyst has an accuracy rate of 63%.
Recent News: On March 14, the European Commission (EC) approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy..
Benzinga Pro's real-time newsfeed alerted to latest BMY news

CVS Health Corporation CVS

Dividend Yield: 3.97%
Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 67%.
Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 79%.
Recent News: On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation.
Edge Stock Ratings: 62.89 Momentum score with Value at 40.46.